SV2A

SV2A
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesSV2A, SV2, synaptic vesicle glycoprotein 2A
External IDsMGI: 1927139 HomoloGene: 32237 GeneCards: SV2A
Gene location (Human)
Chr.Chromosome 1 (human)[1]
BandNo data availableStart149,903,318 bp[1]
End149,917,882 bp[1]
RNA expression pattern
More reference expression data
Orthologs
SpeciesHumanMouse
Entrez

9900

64051

Ensembl

ENSG00000159164

ENSMUSG00000038486

UniProt

Q7L0J3

Q9JIS5

RefSeq (mRNA)

NM_014849
NM_001278719
NM_001328674
NM_001328675

NM_022030

RefSeq (protein)

NP_001265648
NP_001315603
NP_001315604
NP_055664

NP_071313

Location (UCSC)Chr 1: 149.9 – 149.92 MbChr 1: 96.18 – 96.2 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Synaptic vesicle glycoprotein 2A is a ubiquitous synaptic vesicle protein that in humans is encoded by the SV2A gene.[5][6][7] The protein is targeted by the anti-epileptic drugs (anticonvulsants) levetiracetam and brivaracetam.[8]

See also

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000159164 - Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000038486 - Ensembl, May 2017
  3. "Human PubMed Reference:".
  4. "Mouse PubMed Reference:".
  5. Bajjalieh SM, Peterson K, Linial M, Scheller RH (Mar 1993). "Brain contains two forms of synaptic vesicle protein 2". Proceedings of the National Academy of Sciences of the United States of America. 90 (6): 2150–4. PMC 46043Freely accessible. PMID 7681585. doi:10.1073/pnas.90.6.2150.
  6. Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, Scheller RH, Chavkin C, Bajjalieh SM (Dec 1999). "Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)". Proceedings of the National Academy of Sciences of the United States of America. 96 (26): 15268–73. PMC 24809Freely accessible. PMID 10611374. doi:10.1073/pnas.96.26.15268.
  7. "Entrez Gene: SV2A synaptic vesicle glycoprotein 2A".
  8. Ulloa CM, Towfigh A, Safdieh J (2009). "Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures". Neuropsychiatric Disease and Treatment. 5: 467–76. PMC 2747386Freely accessible. PMID 19777068. doi:10.2147/ndt.s4844.

Further reading


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.